Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 19 05 2019
accepted: 19 10 2019
pubmed: 28 10 2019
medline: 8 1 2021
entrez: 26 10 2019
Statut: ppublish

Résumé

To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects. A short-term prospective study was designed. Sixty-seven normotensive subjects were recruited. Patients were divided into two groups. The daily group (DG) (n = 18) was instructed to take the supplement between 22:00 and 23:00 (before sleeping) for 3 consecutive days. IOP was measured from 10.00 to 11.00 am the day before treatment and during the 3 days of experiment. The acute group (AG) (n = 49) was instructed to take the supplement after the second measure (11.00) of the second day. IOP was measured 1 h and just before the intake of the supplement and 1 and 2 h after. All measurements in this group were taken 1 day before without any supplement (control) and the day of experiment. The DG group showed a significant decrease in IOP after supplement intake in all days of experiment, from 14.9 ± 3.4 mm Hg to 13.8 ± 2.9 mm Hg after 3 days of experiment (p value < 0.001). For AG, IOP did not change during the control day; however, a reduction of 1 mm Hg was found 2 and 3 h after supplement intake, from 15.7 ± 2.5 mm Hg to 14.7 ± 2.5 mm Hg and 15.1 ± 2.7 mm Hg, respectively, being statistically significant (p value < 0.001). The supplement based on melatonin was able to reduce the IOP in normotensive subjects after 2 h of intake. Moreover, the daily intake showed a reduction in IOP during the 3 days of experiment.

Identifiants

pubmed: 31650354
doi: 10.1007/s10792-019-01199-1
pii: 10.1007/s10792-019-01199-1
doi:

Substances chimiques

Antioxidants 0
Melatonin JL5DK93RCL

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-422

Références

J Ocul Pharmacol Ther. 2013 Feb;29(1):61-7
pubmed: 23046438
Ophthalmic Physiol Opt. 2015 Mar;35(2):201-5
pubmed: 25600174
Curr Eye Res. 1988 Jul;7(7):649-53
pubmed: 3416618
Clin Exp Ophthalmol. 2012 May-Jun;40(4):341-9
pubmed: 22356435
Auton Neurosci. 2009 May 11;147(1-2):14-9
pubmed: 19176290
Eur J Pharmacol. 2013 Feb 15;701(1-3):213-7
pubmed: 23270715
J Pineal Res. 2003 Jan;34(1):75-8
pubmed: 12485375
Exp Mol Pathol. 2011 Apr;90(2):231-7
pubmed: 21241689
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Acta Ophthalmol (Copenh). 1993 Apr;71(2):185-8
pubmed: 8333263
Optom Vis Sci. 2008 Jan;85(1):61-6
pubmed: 18174841
Pharmacol Ther. 2007 Mar;113(3):507-22
pubmed: 17229466
Molecules. 2010 Jan 20;15(1):442-59
pubmed: 20110903
Acta Neurobiol Exp (Wars). 1994;54 Suppl:57-64
pubmed: 7801793
Anesth Analg. 2009 Apr;108(4):1146-51
pubmed: 19299777

Auteurs

Gonzalo Carracedo-Rodríguez (G)

Ocupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain. jgcarrac@ucm.es.

Alejandro Martínez-Águila (A)

Avizor S.A., Madrid, Spain.

Candela Rodriguez-Pomar (C)

Avizor S.A., Madrid, Spain.

Julia Bodas-Romero (J)

Ocupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.

Juan Sanchez-Naves (J)

Ocupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.

Jesús Pintor (J)

Ocupharm Diagnostics Group Research, Faculty of Optic and Optometry, Department of Optometry and Vision, University Complutense of Madrid, C/Arcos del Jalon 118, 28032, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH